Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
NCT03341871 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1095
Last updated 2021-09-20
Summary
This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.
Conditions
- Hepatitis C Virus (HCV)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AbbVie Inc. · AbbVie
Eligibility
- Min Age
- 0 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-12-27
- Primary Completion
- 2020-09-15
- Completion
- 2020-09-15
Countries
- Japan
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
NCT03069365 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
NCT04903626 ·Status: COMPLETED ·Phase: PHASE3
-
Glecaprevir/Pibrentasvir Real-world Study in China
NCT03941821 ·Status: UNKNOWN
-
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
NCT03235349 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
NCT03067129 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
NCT02629172 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
NCT03222583 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
NCT03117569 ·Status: COMPLETED ·Phase: PHASE3
-
Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation
NCT03868163 ·Status: COMPLETED
-
A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation
NCT04189627 ·Status: COMPLETED
-
Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
NCT07040319 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis
NCT04352309 ·Status: COMPLETED
-
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
NCT04577482 ·Status: COMPLETED
-
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
NCT03092375 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
NCT02939989 ·Status: COMPLETED ·Phase: PHASE3
-
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
NCT04042740 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
NCT03740230 ·Status: COMPLETED
-
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
NCT02634008 ·Status: COMPLETED ·Phase: PHASE3
-
Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C
NCT00629824 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
NCT02441283 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
NCT03855917 ·Status: RECRUITING ·Phase: PHASE4
-
Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2
NCT02945228 ·Status: COMPLETED
-
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
NCT01753570 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
NCT04214028 ·Status: COMPLETED
-
36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8
NCT01683786 ·Status: UNKNOWN ·Phase: PHASE4